Evidence map›Paper›PMID 25977298›Full record

ArticleNucleic acids research2015

Heterologous protein production using euchromatin-containing expression vectors in mammalian cells.

Katalin Zboray, Wolfgang Sommeregger, Edith Bogner, Andreas Gili, Thomas Sterovsky, Katharina Fauland, Beatrice Grabner, Patricia Stiedl, Herwig P Moll, Anton Bauer and 2 more

Open access · goldAbstract read
In one paragraph

Article in Nucleic acids research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 50 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Functional Trimeric SARS-CoV-2 Envelope Protein Expressed in Stable CHO Cells.Frontiers in bioengineering and biotechnology · 2021
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Oxygen Uptake Rate Soft-Sensing via DynamicFrontiers in bioengineering and biotechnology · 2019
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Katalin ZborayLudwig Boltzmann Institute for Cancer Research (LBI-CR), Vienna, 1090, Austria.
Wolfgang SommereggerVienna Institute of BioTechnology, Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, 1190, Austria Polymun Scientific GmbH, Klosterneuburg, 3400, Austria.
Edith BognerLudwig Boltzmann Institute for Cancer Research (LBI-CR), Vienna, 1090, Austria.
Andreas GiliPolymun Scientific GmbH, Klosterneuburg, 3400, Austria.
Thomas SterovskyPolymun Scientific GmbH, Klosterneuburg, 3400, Austria.
Katharina FaulandPolymun Scientific GmbH, Klosterneuburg, 3400, Austria.
Beatrice GrabnerLudwig Boltzmann Institute for Cancer Research (LBI-CR), Vienna, 1090, Austria.
Patricia StiedlLudwig Boltzmann Institute for Cancer Research (LBI-CR), Vienna, 1090, Austria.
Herwig P MollInstitute of Pharmacology, Center of Physiology and Pharmacology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria.ORCID http://orcid.org/0000-0001-6438-9068
Anton BauerThe Antibody Lab, Vienna, 1210, Austria.
Renate KunertVienna Institute of BioTechnology, Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, 1190, Austria renate.kunert@boku.ac.at.
Emilio CasanovaLudwig Boltzmann Institute for Cancer Research (LBI-CR), Vienna, 1090, Austria Institute of Pharmacology, Center of Physiology and Pharmacology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria emilio.casanova@lbicr.lbg.ac.at.
Ludwig Boltzmann Institute for Cancer Research · ATPolymun (Austria) · ATComprehensive Cancer Center Vienna · ATBOKU University · AT

Funding

Austrian Science Fund FWF P 25599Austrian Science Fund FWF W 1224
6 · The paper itself

Abstract

Upon stable cell line generation, chromosomal integration site of the vector DNA has a major impact on transgene expression. Here we apply an active gene environment, rather than specified genetic elements, in expression vectors used for random integration. We generated a set of Bacterial Artificial Chromosome (BAC) vectors with different open chromatin regions, promoters and gene regulatory elements and tested their impact on recombinant protein expression in CHO cells. We identified the Rosa26 BAC as the most efficient vector backbone showing a nine-fold increase in both polyclonal and clonal production of the human IgG-Fc. Clonal protein production was directly proportional to integrated vector copy numbers and remained stable during 10 weeks without selection pressure. Finally, we demonstrated the advantages of BAC-based vectors by producing two additional proteins, HIV-1 glycoprotein CN54gp140 and HIV-1 neutralizing PG9 antibody, in bioreactors and shake flasks reaching a production yield of 1 g/l.

Indexed as

Chromosomes, Artificial, BacterialGenetic VectorsAnimalsAntibodies, NeutralizingCHO CellsCricetinaeCricetulusEuchromatinGlycoproteinsHIV-1HIV AntibodiesHuman Immunodeficiency Virus ProteinsHumansImmunoglobulin Fc FragmentsRecombinant ProteinsAntibodies, NeutralizingEuchromatinGlycoproteinsHIV AntibodiesHuman Immunodeficiency Virus ProteinsImmunoglobulin Fc FragmentsRecombinant Proteins

Identifiers

PMID25977298
PMCPMC4652741
OpenAlexW1501712342

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.